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In the wake of the Portuguese vaccination program 50th anniversary it seems appropriate to review vaccination in patients
with systemic lupus erythematosus. Controversial issues as regards the association between autoimmune diseases, infections, and
vaccines are discussed as well as vaccine safety and efficacy issues as regards chronic immunosuppressant (IS) drug therapy. After
a brief overview of national policies, specific recommendations are made as regards vaccination for adult patients with SLE with a
particular focus on current IS therapy and unmet needs.
1. Introduction
Vaccines induce long lasting protective immunity against
microbial pathogens, prevent clinically relevant infections,
and constitute one of the most important medical inter-
ventions ever. Nevertheless, vaccination plans differ across
nations in several respects: they are not always free of
charge nor compulsory, not all schools require a vaccination
certificate, there are different brands and combinations,
boosters are given at different times and in some areas of
the world, and due to political interference, vaccination is
actually banned [1]. This review describes the Portuguese
National Vaccination Plan and provides the clinician with
an easy guide to the expected vaccination status according
to a patient’s age. Vaccine side-effects with a focus on
autoimmunity and specific indications for vaccination in SLE
patients are discussed together with the expected impact of
immunosuppression upon vaccine efficacy and safety.
2. The Portuguese National Vaccination Plan
TheNational Vaccination Plan (NVP) in Portugal commem-
orates 50 years in 2015. It was officially started in 1965
and is free of charge for all, including migrants. It has
also been continuously updated by governmental decree up
until June 2015, when pneumococcal conjugate vaccine to
newborns was added [2]. Of note, there are also specific
recommendations for unvaccinated adult immigrants [3].
The state also actively implements rubella vaccination to
every nonpregnant woman aged over 18 whose vaccination
status is unknown, even in the postpartum period. Only
diphtheria and tetanus are compulsory in Portugal, with
revaccination being recommended every 10 years. Never-
theless, vaccination denial is rarely reported [4], refusal is
generally met with disapproval, and vaccination procedures
are highly regulated. In addition, should patients lose their
vaccination record, itmay be recovered through a registration
database used in every health centre since the year 2000 [5].
All nationally administered vaccines are imported.
Most of the information on current rates of infection is
available from websites issued by the Portuguese Directorate
General for Health. Diphtheria, poliomyelitis, rubella, and
measles have been eradicated in Portugal [6] but there are still
sporadic reports of rural tetanus in unvaccinated individuals
[7], pertussis in the first year of life [8], and mumps [9].
Furthermore, there is still a notoriously high estimated
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Table 1: (a) Vaccination, (b) vaccination as part of NVP, (c) ages at which vaccination is administered, and (d) age above which patients are
not expected to have been vaccinated in Portugal up to December 2015; m: months; y: years.
(a) Infection (b) Vaccination as part of NVP (c) Age of administration (m or y)
(d) Age (y) above
which patients are
not expected to be
vaccinated
Pertussis 1963–1965 2m 52
Poliomyelitis 1965 2m 50
Mumps and
rubella 1974 12m 41
Measles 1987 12m 44
Hepatitis B 2000 (0 + 13 years old at onset of campaign) Birth 28
Haemophilus
influenzae B 2000 2m 28
Human papilloma
virus 2008 (13 y), 2009 (17 y) 12 y 20–23
Meningococcal C 2006 12m 10
incidence of hepatitis B (1.98/100000) [10] and tuberculosis
(21.6/100000) [11], the latter remaining one of the highest in
Western Europe. Accordingly, the latest NVP has been very
recently updated [12].
In Portugal, depending on year of vaccine introduction
and patient age, some patients are not expected to have been
vaccinated (Table 1). For BCG, it is difficult to provide such
an age estimate because there was a revaccination policy for
Mantoux anergic individuals (the latter was stopped in 2005).
Nevertheless, BCG vaccination at birth was implemented in
1963 and the typical vaccination scar may be recognized. Of
note, hepatitis A vaccination is not part of the NVP but a
recent Portuguese study showed that individuals under 25
years of age are at particular risk of infection [13].
3. The Etiological Role for Infections and
Vaccination in Autoimmune Diseases
Vaccines are not without risk and the degree of vaccine-
related risk should always be compared to that associated
with the corresponding natural infection. The issue of an
etiological role for infections and vaccination in autoimmune
diseases (AID) remains controversial. Autoimmunity is gen-
erally assumed to result from complex interaction between
genetic traits and environmental factors and therefore it
may be argued that until the pathogenesis of AID is fully
understood, the real risk of an infection or vaccination cannot
be clearly defined. Furthermore, autoimmune responses are
not necessarily accompanied by any clinical manifestation
and may precede disease expression and their frequency is
inversely related to a global decline in infections [14]. In
addition, epidemiological studies are difficult, as humans
accumulate many infections by the time early adulthood
is reached and while infections are common, AID are
much rarer diseases. Insomuch as several infections have
been associated with the onset of AID, both experimentally
and in humans [15], distinguishing temporal association
from causality remains a daunting task, exemplified by
Table 2: Reported associations between vaccination and autoim-
mune diseases.
Vaccine/adjuvant Disease
Measles, mumps, and rubella Immune thrombocytopenicpurpura [19]
Hepatitis B vaccine 1991–1997 Multiple sclerosis [65], onestudy
H1N1 influenza vaccine in 2009 Narcolepsy [66]
Hepatitis B vaccination Undifferentiated connectivetissue disease [67, 68]
Human papilloma virus Ovarian failure and lupus [69]
Table 3: Lack of associations between vaccination and autoimmune
diseases.
Vaccine/adjuvant Disease
Hepatitis B vaccine 1991–1997 Multiple sclerosis [70], 5studies
Haemophilus influenzae type B Type 1 diabetes mellitus [71]
Measles, mumps, and
rubella/thimerosal Autism, 20 studies [72]
Tetanus, influenza, and hepatitis B Rheumatoid arthritis [73]
the link between narcolepsy and the H1N1 strain of influenza
epidemic described in Northern Europe [16], but not in
the USA [17]. Vaccine-related AID has been convincingly
demonstrated, an example of which is the Guillain-Barre´
syndrome specifically associatedwith the 1976-77 vaccination
campaign using the A/New Jersey/8/76 swine-flu vaccine
[18]. Other rarely described associations have been described
(Table 2).
Measles infection itself is associated with autoimmune
thrombocytopenia [19] and prior suspicions of risks for
multiple sclerosis, type 1 diabetes, autism, and rheumatoid
arthritis have been subsequently disproven (Table 3). Adju-
vants licensed for human use are coadministered in all
except live vaccines, to enhance immunogenicity [20], and
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mostly consist of aluminium phosphate/hydroxide, oil in
water emulsions (squalene), and liposomes [21]. Aluminium
in vaccines and diet has been convincingly shown to lack
adverse effects in infants in the first year of life [22] but
aluminium itself, squalene, and all other currently used
adjuvants have been associatedwith autoimmunity in a recent
collection of reports grouping gulf war syndrome, siliconosis,
macrophagic myofasciitis, and postvaccination syndrome
collectively known as ASIA, autoimmune/inflammatory syn-
drome. In ASIA, the causative role of adjuvants is based on
experimental models for which several immune-mediated
mechanisms have been proposed [23]. An attempt to establish
causality has to be done on a case-by-case basis, through
the demonstration of a consistent nonrandom temporal
association between AID and vaccination. So far, there are
no minimum specific criteria established for AID induced
by vaccination diagnosis and studies are awaited to ver-
ify this hypothesis. Whether SLE drug therapies such as
hydroxychloroquine are protective in this respect remains
speculative.
4. Vaccination Status in SLE Patients
according to the Portuguese National
Vaccination Program
According to EULAR recommendations, vaccination status
should be assessed in the initial workup of patients with
autoimmune conditions [24]. It is expected to vary depending
on the patient’s age and corresponding NVP. In clinical
practice one should bear in mind that SLE mostly affects
women and that the mean age of diagnosis is 31 years
[25]. With reference to Table 1, when the schedule of the
Portuguese NVP is taken into consideration, the only vac-
cination that remains a real concern in Portuguese patients
is that against human papilloma virus (HPV). In the general
population, epidemiological studies document a significant
risk of infection until the age of 50, such that sexually active
women are thought to potentially benefit from vaccination
[26, 27].This benefit is expected to be even higher in patients
with SLE due to higher rates of persistent HPV infection,
high-grade cervical dysplasia, and cervical cancer [28–31].
Pertussis,Haemophilus influenzae type B, andMeningococcal
C would generally only be expected to occur in infants but
the latter two are of particular concern in splenectomised
patients. As already mentioned, poliomyelitis, measles, and
rubella have been eradicated in Portugal. In the light of
the recent influx of patients into Europe, special attention
should nevertheless be paid to the following vaccinations:
Haemophilus influenzae typeB,Neisseriameningitidis, rubella
(for women of childbearing age), tetanus, and hepatitis
A and B. It must be emphasized that vaccination should
preferably be performed in patients with stable disease [24]
and as a general rule, whenever possible, titres should be
checked, infection excluded, and vaccination administered
accordingly.
Table 4: Vaccine recommendations in adult Portuguese patients
with systemic lupus erythematosus.
Diphtheria and tetanus Every 10 years
Human papilloma virus Sexually active females
Seasonal influenza Yearly
Pneumococcal polysaccharide Repeat once after 5 years [74]
Pneumococcal conjugate Single administration [75]
5. Recommended Vaccines in SLE Patients
There are no clinically applicable scores that allow for the
prediction of individual risk of infections in patients with
SLE, particularly in those patients on immunosuppressive
(IS) drugs which generally increase the risk of infection.
Infection is, at present, one of the leading causes of death in
SLE patients [25, 32, 33]. However, most bacterial, viral, fun-
gal, and other infections that occur in SLE patients, namely,
Escherichia coli, Staphylococcus aureus [34], cytomegalovirus,
parvovirus B19, herpes simplex and Epstein-Barr virus [35],
Cryptococcus neoformans, Candida albicans [36], and Pneu-
mocystis [37], are not preventable by vaccines, as these have
as yet to be developed and childhood/adolescent immu-
nization against these pathogens will be highly desirable
once these become available. In stark contrast, there are
effective vaccines against invasive Streptococcus pneumoniae
infections, to which SLE patients are particularly prone [38]
and which are therefore recommended. Other infections of
epidemic/pandemic nature such as influenza cause signifi-
cant morbidity and mortality in the general population and
yearly influenza vaccination is also recommended in patients
with SLE [39, 40]. These recommendations are put forward
by expert panels and take into account the frequent use of IS
medication despite a lack of evidence that SLE patients are
more frequently or severely affected by influenza or present
additional risks of bacterial superinfection due to corticos-
teroid use [41]. In Portugal, pneumococcal polysaccharide
vaccine and annual influenza vaccines are optional and
partially state subsidized while the pneumococcal conjugate
vaccine is not state supported for adults. Optimally, both
pneumococcal vaccines should be administered following
specific administration timings recently reviewed in detail
[42]. Vaccinations commonly used in adult Portuguese SLE
patients are presented in Table 4.
6. The Effect of Immunosuppressive Drugs on
Vaccine Efficacy and Safety
Drugs used in chronic immunosuppression of SLE patients
have a multiplicity of targets, may deplete cellular subsets,
target intracellular signals involved in B and T-cell activation,
and inhibit macrophage function. Few studies have system-
atically addressed the possibility that the most commonly
chronically used IS drugs affect the rates of seroconversion
after influenza and pneumococcal vaccination and even fewer
have studied the long term protective effect of vaccination.
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SLE patients may have a blunted immune response
to influenza vaccination [43]. Exceptionally, a single study
evaluated the effect of hydroxychloroquine and a stable
dose of prednisolone and azathioprine on the rate of sero-
conversion one month following influenza vaccination and
found that only azathioprine was associated with lower
influenza antibodies [44]. It is currently unknown whether
SLE patients maintain their titres following vaccination
allowing for sufficient protection during the whole influenza
season. Although the effect ofmycophenolatemofetil (MMF)
and rituximab (RTX) has not specifically been assessed in
lupus patients, MMF diminishes influenza seroconversion
in transplant recipients [45] and RTX has a similar effect
in rheumatoid arthritis (RA) patients [46, 47]. In the lat-
ter patients, methotrexate does not significantly diminish
humoral responses to vaccination [48, 49].
SLE patients may display nonprotective responses to the
pneumococcal vaccine but no correlation has been made
with the type and dose of IS [50]. In SLE patients, hep-
atitis B vaccine response may be impaired and serological
responses should be assessed after vaccination [51]. RTX
reduces responses to pneumococcal vaccine but this has
only been studied in RA [47, 52]. Ideally, patients should
be vaccinated before undergoing B cell depletion therapy.
Belimumab does not seem to reduce vaccine antibodies to
influenza, pneumococcal, and tetanus vaccines [53]. As a
general rule, inactivated vaccines should be administered at
least 14 days before initiation of immunosuppressive therapy
to optimize immunogenicity.
It should be noted that even though childhood chick-
enpox can be associated with severe complications [54] and
the vaccine is safe and effective [54, 55], chickenpox immu-
nization is only offered to children in Australia, Canada,
Germany, Korea, Qatar, Saudi Arabia, Taiwan, Uruguay,
Sicily, andMadrid [56].The vaccine is live,may cause dissem-
inated infection in immunocompromised patients [57], and
effectively remains excluded frommost vaccination programs
as there are still widespread worries that it may increase
the risk of chickenpox and shingles in older people. On the
other hand, herpes zoster is still the most common viral
infection in SLE patients treated with cyclophosphamide and
mycophenolate mofetil [58]. There is a zoster vaccine which
is 50 to 70% effective. It has been licensed since 2006 for
immunization of immunocompetent individuals over age
60 years with no history of recent zoster [59, 60] and has
also been shown to be effective between 50 and 59 years of
age [61]. It cannot however be routinely recommended in
SLE patients because it is a live vaccine which may pose a
danger of generalized and even fatal infections in IS patients.
It is not recommended in patients that test negative for
varicella-specific antibodies, indicating absence of previous
exposure. According to EULAR guidance, zoster vaccination
is contraindicated when steroids are used for ≥14 days, at a
dose of 20mg of prednisone equivalent or higher and with
the use of azathioprine ≥3.0mg/kg/day or methotrexate at
≥0.4mg/kg/week [24]. Results of a recent trial are awaited,
intended to test safety, tolerability, and immunogenicity of
the zoster vaccine in patients receiving chronic/maintenance
corticosteroids [62]. No information onMMF or belimumab
is available as regards zoster vaccination safety. As a general
rule it seems prudent to check immune reconstitution in
patients that have been subjected to IS therapy in high
dosage or for long periods of time before zoster vaccination
is prescribed. Live vaccines are contraindicated in patients
undergoing biological therapy [42].
Detailed information about traveler needs and emerging
infections [21] is beyond the scope of this paper. As already
mentioned, live vaccines such as for yellow fevermay cause an
infection in significantly IS individuals. On the other hand,
pathogen born yellow fever infection has a high mortality.
Personalized decisions should therefore be made as regards
vaccine administration, therapy delays, or drug holidays. Of
note, yellow fever vaccine is safe in HIV positive individuals
with adequate CD4+ T-cell counts [63] and in transplant
recipients [64].
7. Conclusion
In conclusion, the overall balance is in favour of vaccination
in patients with SLE. Infection/vaccine induced AID remains
a theoretical possibility and there are documented effects of
IS drugs on vaccine efficacy and safety. Vaccination records
according to NVP should be routinely performed in the
initial workup of SLE patients and additional vaccinations
prescribed as required, bearing in mind that vaccination
should be preferably performed when the disease is in remis-
sion. Seasonal influenza, pneumococcal, and HPV vaccina-
tion are actively encouraged. Whenever possible, protective
titres should be checked for rubella and hepatitis A and B,
preventing unnecessary vaccination. Live vaccination must
be individualized and may be performed in non- or mildly
immunosuppressed patients but data is awaited regarding
their safety in patients that require higher dosages of IS. As
a whole, vaccination is safe and should be supported as part
of standard of care in patients with SLE in whom infections
are a significant cause of morbidity and mortality. It is also
hoped that new vaccines will greatly contribute to progress in
improving healthcare and that old vaccines will be optimized
to provide extended protection.
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